Dashboard
Manage Tickers

ACRVAcrivon Therapeutics, Inc.

Nasdaq acrivon.com


$ 8.22 $ -0.09 (-1.09 %)    

Thursday, 09-May-2024 15:57:40 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 441.33 $ 0.96 (0.22 %)
DIA $ 394.43 $ 3.52 (0.9 %)
SPY $ 520.56 $ 2.98 (0.58 %)
TLT $ 90.69 $ 0.44 (0.49 %)
GLD $ 216.93 $ 3.37 (1.58 %)
$ 8.14
$ 8.30
$ 0.00 x 0
$ 0.00 x 0
$ 8.19 - $ 8.69
$ 3.19 - $ 14.30
227,376
na
170M
$ 0.87
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-28-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-11-2023 06-30-2023 10-Q
4 05-09-2023 03-31-2023 10-Q
5 03-28-2023 12-31-2022 10-K
6 12-15-2022 09-30-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

ladenburg-thalmann-downgrades-acrivon-therapeutics-to-neutral
Ladenburg Thalmann Downgrades Acrivon Ther...
04/29/2024 13:12:45

Ladenburg Thalmann analyst Aydin Huseynov downgrades Acrivon Therapeutics (NASDAQ:ACRV) from Buy to Neutral.

bmo-capital-maintains-outperform-on-acrivon-therapeutics-raises-price-target-to-25
BMO Capital Maintains Outperform on Acrivo...
04/26/2024 18:01:56

BMO Capital analyst Etzer Darout maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Outperform and raises the price target ...

jmp-securities-maintains-market-outperform-on-acrivon-therapeutics-raises-price-target-to-17
JMP Securities Maintains Market Outperform...
04/25/2024 16:43:24

JMP Securities analyst Silvan Tuerkcan maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Market Outperform and raises the ...

piper-sandler-maintains-overweight-on-acrivon-therapeutics-raises-price-target-to-30
Piper Sandler Maintains Overweight on Acri...
04/25/2024 12:53:55

Piper Sandler analyst Joseph Catanzaro maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Overweight and raises the price t...

hc-wainwright--co-reiterates-buy-on-acrivon-therapeutics-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Acri...
04/25/2024 11:29:58

HC Wainwright & Co. analyst Emily Bodnar reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and maintains $20 pric...

acrivon-therapeutics-shares-are-trading-higher-after-the-company-reported-initial-clinical-data-for-acr-368-and-pipeline-program-progress-today-at-a-corporate-rd-event
Acrivon Therapeutics shares are trading hi...
04/25/2024 10:13:54

acrivon-therapeutics-reports-a-50-confirmed-overall-response-rate-observed-with-acr-368-in-oncosignature-positive-gynecological-cancers-initial-clinical-validation-of-ap3-patient-selection-platform-demonstrated-ability-to-prospectively-predict-acr-368-recist-responders
Acrivon Therapeutics Reports A 50% Confirm...
04/24/2024 20:44:56

acrivon-therapeutics-reports-initial-positive-clinical-data-for-acr-368-and-pipeline-program-progress-today-at-corporate-rd-event
Acrivon Therapeutics Reports Initial Posit...
04/24/2024 20:44:46

•  Initial ACR-368 Phase 2b clinical data in patients with ovarian or endometrial cancers (n=26; 10 OncoSignature-positive and ...

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
04/24/2024 20:31:44

acrivon-therapeutics-presents-data-at-aacr-annual-meeting-highlighting-capabilities-of-acrivon-predictive-precision-proteomics-for-the-discovery-of-acr-2316-a-novel-selective-wee1pkmyt1-inhibitor-and-the-identification-of-actionable-resistance-mechanisms-to-acr-368
Acrivon Therapeutics Presents Data At AACR...
04/10/2024 12:07:56

ACR-2316, which was internally discovered using biological SAR enabled by AP3 to overcome limitations of benchmark clinical WEE...

crude-oil-down-over-1-cognyte-software-shares-plummet
Crude Oil Down Over 1%; Cognyte Software S...
04/09/2024 18:34:43

U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 0.4% on Tuesday. The Dow traded down 0...

why-tilray-brands-shares-are-trading-lower-by-around-22-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why Tilray Brands Shares Are Trading Lower...
04/09/2024 17:12:29

Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter esti...

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
04/09/2024 16:31:26

dow-dips-150-points-laser-photonics-shares-spike-higher
Dow Dips 150 Points; Laser Photonics Share...
04/09/2024 16:05:23

U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 150 points on Tuesday. The Dow traded...

acrivon-therapeutics-stock-is-soaring-tuesday-whats-going-on
Acrivon Therapeutics Stock Is Soaring Tues...
04/09/2024 13:52:34

Acrivon Therapeutics has entered into a securities purchase agreement to issue and sell 8.235 million shares of its common stoc...

dow-gains-over-50-points-neogen-posts-downbeat-earnings
Dow Gains Over 50 Points; Neogen Posts Dow...
04/09/2024 13:51:06

U.S. stocks traded higher this morning, with the Dow Jones index gaining over 50 points on Tuesday. Following the market openi...

Core News & Articles
Market-Moving News for April 9th
04/09/2024 12:56:00

LASE: 167% | Laser Photonics shares are trading higher after the company announced it secured an order for its LaserTower COMPA...

12-health-care-stocks-moving-in-tuesdays-pre-market-session
12 Health Care Stocks Moving In Tuesday's ...
04/09/2024 12:09:53

acrivon-therapeutics-announces-130m-private-placement-financing
Acrivon Therapeutics Announces $130M Priva...
04/09/2024 11:01:27

ladenburg-thalmann-maintains-buy-on-acrivon-therapeutics-lowers-price-target-to-14
Ladenburg Thalmann Maintains Buy on Acrivo...
04/05/2024 14:41:47

Ladenburg Thalmann analyst Aydin Huseynov maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and lowers the price targe...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION